Second-wave IFN-based triple therapy for HCV genotype 1 infection: Simeprevir, faldaprevir and sofosbuvir

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 60-68

  Asselah, Tarik ^a,b,c   Marcellin, Patrick ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antiviral potency; Direct acting antivirals; Pills burden; Resistance; Safety

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; DANOPREVIR; FALDAPREVIR; INTERFERON; MK 5172; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PILL; RELAPSE; REVIEW; TREATMENT DURATION; UNITED STATES;

ANTIVIRAL POTENCY; DIRECT-ACTING ANTIVIRALS; PILLS BURDEN; RESISTANCE; SAFETY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; OLIGOPEPTIDES; SULFONAMIDES; THIAZOLES; TIME FACTORS; URIDINE MONOPHOSPHATE;

EID: 84890865643     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12424     Document Type: Review

References (25)

1. Maylin S, Martinot M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
2. Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
3. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33(Suppl 1): 93-104.
4. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-nave patients: results from QUEST-1, a phase III trial. International Liver Congress, Amsterdam, poster 1425, 2013.
5. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype -1 infection in treatment-nai{dotless}ve patients: results from QUEST-2, a phase III trial. International Liver Congress, Amsterdam, abstract 1413, 2013.
6. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. AASLD 2013. Abstract 1122.
7. Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients who Relapsed After Previous Interferon-Based Therapy: Results from PROMISE, a Phase III trial [abstract869b]. Presented at Digestive Disease Week; 18-21 May; 2013.
8. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. AASLD 2013. Abstract 1092.
9. Sulkowski MS, Asselah T, Lalezari J, et al. Faldaprevir combined with peginterferon alfa-2a and ribivirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-54.
10. Sulkowski MS, Bourlière M, Bronowicki JP, et al. Faldaprevir combined with peginterferon alfa-2a and ribivirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-63.
11. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-9.
12. Ferenci P, Asselah T, Foster GR, et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomised double blind placebo-controlled phase III trial. 48th Annual Meeting of the EASL 2013. Abstract 1416.
13. Jensen D, Asselah T, Dieterich D, et al. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment- naïve patients with chronic hepatitis C genotype-1 infection. AASLD 2013; Abstract 1088.
14. Jacobson I, Asselah T, Ferenci P, et al. STARTVerso3: a randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. AASLD 2013; Abstract 1100.
15. Rockstroh JK, Nelson M, Soriano V, et al. STARTVerso 4 phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response. AASLD 2013. Abstract 1099.
16. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
17. Marcellin P, Cooper C, Balart L, et al. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013; 145: 790-800.
18. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-7.
19. Bronowicki JP, Pol S, Thuluvath PJ, et al. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C. Antiviral Ther, 2013, in press.
20. Manns M, Vierling JM, Bacon BR, et al. High sustained viral response of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype-1 treatment naive non-cirrhotic patient (EASL). J Hepatol, 2013; 58: Abstract 66.
21. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011; 56: 527-32.
22. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.
23. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
24. Kowdley KV, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT- 450/R, ABT-267, ABT-333 + /- ribavirin in patients with chronic HCV GT1 infection: results from the Aviator study. J Hepatol 2013; 58(Suppl 1): A3.
25. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with or without RBV in genotype 1 treatment-naïve and prior null responder patients: COSMOS. Hepatology 2013, AASLD; LB3.